Medical research advances in personalized cancer vaccines and depression detection

New medical research highlights potential breakthroughs in both oncology and mental health diagnostics. In oncology, a clinical trial involving the mRNA-based vaccine Intismaran, developed by MSD and Moderna, has shown promise in treating melanoma. When combined with the immunotherapy drug Keytruda, the personalized vaccine reduced the risk of melanoma recurrence or spread by 38% over two years compared to immunotherapy alone. This approach uses a patient's specific tumor data to train the immune system to recognize cancer cells, and similar studies are being conducted for kidney, bladder, and lung cancers.

In the field of mental health, researchers from New York University have discovered that biological aging in certain white blood cells may be linked to symptoms of depression. The study, published in The Journals of Gerontology: Series A, suggests that changes in immune cells could eventually assist in the early detection of depression and the customization of treatments. While the research is in its early stages and cannot yet be used for routine clinical diagnosis, it offers a potential biological pathway to understanding symptoms such as anhedonia and hopelessness.